PDF(Pubmed)
Abstract：
OBJECTIVE: The biology of rare pancreatic tumours, which differs from that of ductal pancreatic cancer, requires increased attention. Although the majority of rare pancreatic tumours are benign, it is difficult to decide whether an invasive component exists without complete removal of the lesion, despite considerable progress in diagnosis. We are investigating a large cohort of patients with histologically confirmed epithelial non-ductal non-neuroendocrine neoplasms of the pancreas.
METHODS: Here we analyze long-term survival from patients, who underwent resection of histologically confirmed epithelial non-ductal non-neuroendocrine neoplasms of the pancreas. At our department between Jan 1st, 1999, and Dec 31st, 2019. The median follow-up was 61 (range 0-168) month. All statistical analyses were performed using SPSS 26.0 (IBM, Chicago, IL, USA) software.
RESULTS: 46 patients (48%) were followed up for more than 5 years, 18 patients (19%) for more than 10 years. The 5-year and 10-year survival rates for rare non-invasive pancreatic tumours were 72% and 55% respectively. The proportion of rare tumour entities (non-ductal and non-neuroendocrine) increased continuously and statistically significantly (p = 0.004) from 4.2 to 12.3% in our clinic between 1999 and 2019. If there is no invasive growth yet, there is a varying risk of malignant degeneration in the course of the disease. Therefore, the indication for pancreatic resection is still the subject of discussion.
CONCLUSIONS: The long-term prognosis of rare epithelial pancreatic tumours after R0 resection-even if they are already malignant-is much better than that of ductal pancreatic cancer.
METHODS: Here we analyze long-term survival from patients, who underwent resection of histologically confirmed epithelial non-ductal non-neuroendocrine neoplasms of the pancreas. At our department between Jan 1st, 1999, and Dec 31st, 2019. The median follow-up was 61 (range 0-168) month. All statistical analyses were performed using SPSS 26.0 (IBM, Chicago, IL, USA) software.
RESULTS: 46 patients (48%) were followed up for more than 5 years, 18 patients (19%) for more than 10 years. The 5-year and 10-year survival rates for rare non-invasive pancreatic tumours were 72% and 55% respectively. The proportion of rare tumour entities (non-ductal and non-neuroendocrine) increased continuously and statistically significantly (p = 0.004) from 4.2 to 12.3% in our clinic between 1999 and 2019. If there is no invasive growth yet, there is a varying risk of malignant degeneration in the course of the disease. Therefore, the indication for pancreatic resection is still the subject of discussion.
CONCLUSIONS: The long-term prognosis of rare epithelial pancreatic tumours after R0 resection-even if they are already malignant-is much better than that of ductal pancreatic cancer.
摘要：
目的：罕见胰腺肿瘤的生物学，不同于导管胰腺癌，需要更多的关注。尽管大多数罕见的胰腺肿瘤是良性的，如果不完全切除病变，很难确定是否存在侵入性成分，尽管在诊断方面取得了相当大的进展。我们正在调查大量经组织学证实的胰腺上皮非导管非神经内分泌肿瘤患者。
方法：在这里，我们分析了患者的长期生存率，接受组织学证实的胰腺上皮非导管非神经内分泌肿瘤切除术的患者。1月1日之间在我们部门，1999年和12月31日，2019.中位随访时间为61（范围0-168）个月。所有统计分析均使用SPSS26.0(IBM，芝加哥,IL,美国）软件。
结果：46例（48%）随访5年以上，18例(19%)患者10年以上。罕见的非侵袭性胰腺肿瘤的5年和10年生存率分别为72％和55％。在1999年至2019年期间，我们的诊所中罕见肿瘤实体（非导管和非神经内分泌）的比例从4.2％连续增加到12.3％（p=0.004）。如果还没有侵入性生长，在疾病的过程中，恶性变性的风险各不相同。因此,胰腺切除的适应症仍是讨论的主题.
结论：R0切除后的罕见上皮性胰腺肿瘤的长期预后-即使它们已经是恶性的-比导管胰腺癌的预后要好得多。
方法：在这里，我们分析了患者的长期生存率，接受组织学证实的胰腺上皮非导管非神经内分泌肿瘤切除术的患者。1月1日之间在我们部门，1999年和12月31日，2019.中位随访时间为61（范围0-168）个月。所有统计分析均使用SPSS26.0(IBM，芝加哥,IL,美国）软件。
结果：46例（48%）随访5年以上，18例(19%)患者10年以上。罕见的非侵袭性胰腺肿瘤的5年和10年生存率分别为72％和55％。在1999年至2019年期间，我们的诊所中罕见肿瘤实体（非导管和非神经内分泌）的比例从4.2％连续增加到12.3％（p=0.004）。如果还没有侵入性生长，在疾病的过程中，恶性变性的风险各不相同。因此,胰腺切除的适应症仍是讨论的主题.
结论：R0切除后的罕见上皮性胰腺肿瘤的长期预后-即使它们已经是恶性的-比导管胰腺癌的预后要好得多。
